Research Reports | Market Assessment
September 2018

Breast Cancer | Current Treatment: Physician Insights | US | 2018

Hormone receptor (HR)-positive/HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status, resectability, site of metastasis, and prior treatment received. The recent approval of three CDK4/6 inhibitors in the metastatic setting in the United States (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) has altered physicians’ prescribing habits and created new dynamics in treatment sequencing. Furthermore, the approval of AstraZeneca’s PARP inhibitor Lynparza for metastatic gBRCA-positive, HER2-negative breast cancer patients has given an additional treatment option to physicians for this subgroup of patients who are also HR-positive.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports